<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02478775</url>
  </required_header>
  <id_info>
    <org_study_id>15-0474</org_study_id>
    <secondary_id>UL1TR001082</secondary_id>
    <nct_id>NCT02478775</nct_id>
  </id_info>
  <brief_title>Dysregulation of FSH in Obesity: Functional and Statistical Analysis</brief_title>
  <official_title>Dysregulation of Follicle Stimulating Hormone (FSH) in Obesity: Functional and Statistical Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Excess maternal weight, especially obesity, influences almost every aspect of fertility, from&#xD;
      conception to problems during pregnancy. The investigators will use novel statistical methods&#xD;
      to clarify the hormonal changes behind reproductive health conditions. A better understanding&#xD;
      of reproductive hormonal changes in obese women may offer a way to identify new treatments.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis. Insufficient FSH (Follicle-stimulating hormone) pulsatility, as seen in obesity,&#xD;
      results in inadequate folliculogenesis and reduced ovarian steroid and protein production.&#xD;
&#xD;
      AIM: To test the hypothesis that insufficient FSH pulsatility, as seen in obesity, results in&#xD;
      inadequate folliculogenesis and reduced ovarian steroid and protein production. The&#xD;
      investigators will determine if exogenous FSH administered in a pulsatile fashion results in&#xD;
      a significant increase of ovarian hormones in obese women. Serial inhibin B and E2 levels&#xD;
      will be measured in obese and normal weight women undergoing frequent blood sampling studies&#xD;
      before and after GnRH (Gonadotropin-releasing hormone) antagonist blockade.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Actual">March 1, 2021</completion_date>
  <primary_completion_date type="Actual">March 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference between peak inhibin B</measure>
    <time_frame>Every 10 minutes over 10 hours.</time_frame>
    <description>This is defined as the maximum hormone value during the Day2 study minutes after the maximum hormone value during the Day1 study before GnRH antagonist is administered. Participants will be followed for the duration of the hospital stay, an expected average of 26 hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak inhibin B per subject</measure>
    <time_frame>Every 10 minutes over 10 hours.</time_frame>
    <description>Investigators will compute a composite measure of luteinizing hormone (LH) and FSH pulsatility (pulse frequency, and average pulse amplitude) on day 1 and day 2, along with the means of LH and FSH to assess adequacy of GnRH antagonism and FSH stimulation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak E2 per subject</measure>
    <time_frame>Every 10 minutes over 10 hours.</time_frame>
    <description>Investigators will compute a composite measure of luteinizing hormone (LH) and FSH pulsatility (pulse frequency, and average pulse amplitude) on day 1 and day 2, along with the means of LH and FSH to assess adequacy of GnRH antagonism and FSH stimulation.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Obesity</condition>
  <condition>Fertility</condition>
  <arm_group>
    <arm_group_label>Frequent Blood Sampling</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigators will assess the change in inhibin B levels following repeated bolus dosing of recombinant FSH (rFHS) following Degarelix (GnRH antagonist) blockade over a 2-day period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Degarelix (GnRH antagonist)</intervention_name>
    <description>Day-1: Blood samples will be obtained every 10 minutes for 10 hours. After 10 hours of blood samples have been collected, the GnRH antagonist degarelix will be given subcutaneously.</description>
    <arm_group_label>Frequent Blood Sampling</arm_group_label>
    <other_name>Firmagon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant FSH</intervention_name>
    <description>Day-2: Blood samples will again be obtained every 10 minutes for 10 hours. Repeated boluses of exogenous recombinant FSH (rFSH) will be given by IV during this 10 hour visit.</description>
    <arm_group_label>Frequent Blood Sampling</arm_group_label>
    <other_name>rFHS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 21 to 39 years old with regular menstrual cycles every 25-40 days&#xD;
&#xD;
          -  Body mass of 18.5 kg/m2-24.9kg/m2 (normal weight controls) or greater than 30.0 kg/m2&#xD;
             (obese group)&#xD;
&#xD;
          -  Prolactin and thyroid-stimulating hormone (TSH) within normal laboratory ranges at&#xD;
             screening&#xD;
&#xD;
          -  Baseline hemoglobin &gt;11 gm/dl.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of polycystic ovary syndrome (PCOS), defined by the 2003 Rotterdam criteria&#xD;
             as suggested by 2012 NIH Workshop&#xD;
&#xD;
          -  History of chronic disease affecting hormone production, metabolism or clearance or&#xD;
             use of thiazolidinediones or metformin (known to interact with reproductive hormones)&#xD;
&#xD;
          -  Use of hormones affecting hypothalamic-pituitary-gonadal (HPO) axis (such as hormonal&#xD;
             contraceptives) within 3 months of entry&#xD;
&#xD;
          -  Strenuous exercise (&gt;4 hours of intense physical activity per week)&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Breast-feeding&#xD;
&#xD;
          -  Current attempts to conceive&#xD;
&#xD;
          -  Significant recent weight loss or gain&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alex Polotsky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Clinical and Translational Research Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 7, 2015</study_first_submitted>
  <study_first_submitted_qc>June 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2015</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>fertility</keyword>
  <keyword>infertility</keyword>
  <keyword>reproductive hormones</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

